Results 91 to 100 of about 282,663 (297)
Haematologica, 2019 Hydroxyurea is the standard treatment in high-risk patients with polycythemia vera. However, estimates of its effect in terms of clinical outcomes (thrombosis, bleeding, hematologic transformations and mortality) are lacking. We performed a meta-analysis
A. Ferrari +7 more
semanticscholar +1 more source
Catheterization and Cardiovascular Interventions, Volume 105, Issue 7, Page 1535-1544, June 1, 2025.ABSTRACT Background Myeloproliferative neoplasms (MPN) are associated with an increased cardiovascular risk including acute coronary syndrome. However, there is a lack of comprehensive data regarding the rate of percutaneous coronary intervention (PCI), as well as the in‐hospital characteristics and outcomes for MPN patients.
Song Peng Ang +8 more
wiley +1 more source
Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis
Haematologica, 2019 Here we critically evaluate the role of elevated hematocrit as the principal determinant of thrombotic risk in polycythemia and erythrocytosis, defined by an expansion of red cell mass.
Victor R. Gordeuk +2 more
doaj +1 more source
GAMBARAN GEN JAK2 PADA PENDERITA POLISITEMIA VERA DI LABORATORIUM CEBIOR [PDF]
, 2015 Background: Polycythemia vera ( PV ) is one of the myeloproliferative malignancies. The Jak2V617F mutation is found in approximately 96 percent of people with PV. JAK2 gene mutation results in the production of an activated JAK2 protein, which appears to
Faradz, Sultana MH +2 more
core +1 more source
How I Treat Polycythemia Vera.
Blood, 2019 Since its discovery 125 years ago, polycythemia vera (PV) has been a challenge to the clinicians responsible for its diagnosis and management, and the scientists attempting to define its molecular basis.
J. Spivak
semanticscholar +1 more source
Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera
Haematologica, 2017 Up to 20% of patients with polycythemia vera have karyotypic abnormalities at the time of the initial diagnosis. However, the cytogenetic abnormalities in polycythemia vera have not been well characterized and their prognostic impact is largely unknown ...
Guilin Tang +13 more
doaj +1 more source
Transient Spinal Cord Ischemia as Presenting Manifestation of Polycythemia Vera
Case Reports in Neurology, 2011 Spinal arterial vascularization is supplied by a large anastomotic net, making spinal ischemic events far less common than ischemic cerebral strokes. Polycythemia vera, due to blood hyperviscosity and activated platelet aggregation, is associated with a ...
Sónia Costa +3 more
doaj +1 more source
Polycythemia vera treatment algorithm 2018
Blood Cancer Journal, 2018 Recently reported mature survival data have confirmed the favorable prognosis in polycythemia vera (PV), with an estimated median survival of 24 years, in patients younger than age 60 years old.
A. Tefferi, A. Vannucchi, T. Barbui
semanticscholar +1 more source
Polycythemia Vera: New Diagnostic Concept and Its Types
Клиническая онкогематология, 2016 Polycythemia vera (PV) is a clonal Ph-negative myeloproliferative disorder characterized by excessive myeloid proliferation of three hematopoietic cell lineages leading to ineffective myelopoiesis.
AM Kovrigina, VV Baikov
doaj +1 more source
Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. [PDF]
, 2013 To access publisher full text version of this article. Please click on the hyperlink in Additional Links field.Reported survival in patients with myeloproliferative neoplasms (MPNs) shows great variation.
Andersson, Therese M-L +7 more
core +1 more source